

# François Radvanyi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5122624/publications.pdf>

Version: 2024-02-01

148  
papers

11,550  
citations

23567

58  
h-index

30087

103  
g-index

160  
all docs

160  
docs citations

160  
times ranked

12219  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	1.9	741
2	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. <i>Nature Genetics</i> , 1999, 23, 18-20.	21.4	637
3	Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. <i>Cell</i> , 1991, 66, 1095-1104.	28.9	506
4	Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. <i>Bioinformatics</i> , 2004, 20, 3413-3422.	4.1	465
5	Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors. <i>American Journal of Pathology</i> , 2001, 158, 1955-1959.	3.8	427
6	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	12.4	304
7	Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2003, 21, 1912-1921.	1.6	294
8	A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin. <i>Analytical Biochemistry</i> , 1989, 177, 103-109.	2.4	246
9	The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. <i>Cancer Research</i> , 2001, 61, 1265-8.	0.9	245
10	Regional copy number-independent deregulation of transcription in cancer. <i>Nature Genetics</i> , 2006, 38, 1386-1396.	21.4	198
11	FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. <i>Cancer Research</i> , 2003, 63, 8108-12.	0.9	196
12	Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study. <i>Clinical Cancer Research</i> , 2007, 13, 3545-3551.	7.0	189
13	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer</i> , 2016, 2, 37-47.	0.4	184
14	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. <i>Cell Reports</i> , 2014, 9, 1235-1245.	6.4	181
15	Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. <i>Annals of Oncology</i> , 2010, 21, 815-819.	1.2	176
16	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. <i>Human Molecular Genetics</i> , 2005, 14, 1153-1160.	2.9	175
17	Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision. <i>PLoS Computational Biology</i> , 2013, 9, e1003286.	3.2	167
18	Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non-Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2010, 58, 433-441.	1.9	159

#	ARTICLE	IF	CITATIONS
19	Determination of phospholipase A2 activity by a colorimetric assay using a pH indicator. <i>Toxicon</i> , 1987, 25, 1181-1188.	1.6	158
20	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma <i>In situ</i> of the Breast. <i>Clinical Cancer Research</i> , 2008, 14, 1956-1965.	7.0	148
21	Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. <i>European Journal of Human Genetics</i> , 2002, 10, 819-824.	2.8	138
22	Expression of <i>mage</i> genes in transitional-cell carcinomas of the urinary bladder. <i>International Journal of Cancer</i> , 1995, 64, 60-64.	5.1	132
23	Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. <i>European Journal of Cancer</i> , 2015, 51, 45-54.	2.8	131
24	Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. <i>Carcinogenesis</i> , 2006, 27, 740-747.	2.8	128
25	Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. <i>Oncogene</i> , 1999, 18, 7234-7243.	5.9	125
26	Differences in steroid 5 $\alpha$ -reductase iso-enzymes expression between normal and pathological human prostate tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1999, 68, 189-195.	2.5	122
27	Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. <i>Oncogene</i> , 2005, 24, 7094-7104.	5.9	122
28	Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf <i>Journal of Gastroenterology</i> , 2008, 103, 2825-2835.	0.4	118
29	Moderate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice. <i>Nature Genetics</i> , 1997, 15, 190-192.	21.4	117
30	MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. <i>Oncogene</i> , 2006, 25, 5985-5993.	5.9	115
31	A comprehensive modular map of molecular interactions in RB/E2F pathway. <i>Molecular Systems Biology</i> , 2008, 4, 173.	7.2	113
32	Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. <i>Oncogene</i> , 1997, 14, 3059-3066.	5.9	106
33	VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. <i>Bioinformatics</i> , 2006, 22, 2066-2073.	4.1	106
34	Pancreatic beta cells cultured from individual preneoplastic foci in a multistage tumorigenesis pathway: a potentially general technique for isolating physiologically representative cell lines.. <i>Molecular and Cellular Biology</i> , 1993, 13, 4223-4232.	2.3	100
35	A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. <i>Cancer Research</i> , 2015, 75, 4042-4052.	0.9	96
36	Deregulation of Rab and Rab Effector Genes in Bladder Cancer. <i>PLoS ONE</i> , 2012, 7, e39469.	2.5	95

#	ARTICLE	IF	CITATIONS
37	Pax-QNR/Pax-6, a paired box- and homeobox-containing gene expressed in neurons, is also expressed in pancreatic endocrine cells.. <i>Molecular Endocrinology</i> , 1994, 8, 929-938.	3.7	91
38	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> mutated urothelial bladder carcinoma. <i>Journal of Pathology</i> , 2012, 227, 315-324.	4.5	90
39	Bayesian Hierarchical Model for Identifying Changes in Gene Expression from Microarray Experiments. <i>Journal of Computational Biology</i> , 2002, 9, 671-683.	1.6	85
40	Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. <i>Journal of Pathology</i> , 2010, 221, 320-330.	4.5	85
41	Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 7165-7175.	0.9	83
42	Comparison of crotoxin isoforms reveals that stability of the complex plays a major role in its pharmacological action. <i>FEBS Journal</i> , 1993, 214, 491-496.	0.2	81
43	Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. <i>Oncogene</i> , 1997, 14, 323-330.	5.9	80
44	Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. <i>Analytical Biochemistry</i> , 2004, 328, 101-108.	2.4	80
45	Computation of recurrent minimal genomic alterations from array-CGH data. <i>Bioinformatics</i> , 2006, 22, 849-856.	4.1	79
46	8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis. <i>PLoS ONE</i> , 2009, 4, e7239.	2.5	79
47	PI3K/AKT pathway activation in bladder carcinogenesis. <i>International Journal of Cancer</i> , 2014, 134, 1776-1784.	5.1	74
48	Spatial normalization of array-CGH data. <i>BMC Bioinformatics</i> , 2006, 7, 264.	2.6	71
49	Somatic instability of the CTG repeat in mice transgenic for the myotonic dystrophy region is age dependent but not correlated to the relative intertissue transcription levels and proliferative capacities. <i>Human Molecular Genetics</i> , 1998, 7, 1285-1291.	2.9	70
50	Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 148, 181-189.	2.8	70
51	Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. <i>British Journal of Cancer</i> , 2000, 83, 209-214.	6.4	69
52	Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. <i>Carcinogenesis</i> , 2004, 26, 177-184.	2.8	68
53	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2019, 8, e1581556.	4.6	68
54	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	67

#	ARTICLE	IF	CITATIONS
55	A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. <i>Journal of the National Cancer Institute</i> , 2011, 103, 47-60.	6.3	66
56	A prognostic DNA signature for T1T2 node-negative breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 1125-1134.	2.8	64
57	Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas. <i>Cancer Research</i> , 2005, 65, 1376-1383.	0.9	62
58	Independent Component Analysis for Unraveling the Complexity of Cancer Omics Datasets. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4414.	4.1	62
59	Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. <i>Clinical Cancer Research</i> , 2003, 9, 257-63.	7.0	62
60	Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. <i>Molecular Cancer</i> , 2005, 4, 15.	19.2	61
61	Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer <sup>*1</sup> . <i>Human Pathology</i> , 1998, 29, 1005-1012.	2.0	57
62	Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. <i>Journal of Medical Genetics</i> , 2010, 47, 859-862.	3.2	57
63	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. <i>European Urology</i> , 2020, 78, 682-687.	1.9	57
64	Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. <i>Carcinogenesis</i> , 2000, 21, 2211-2218.	2.8	56
65	An <sc>FGFR</sc> 3/ <sc>MYC</sc> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	54
66	Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 2164.	2.8	53
67	Milk fat globule-epidermal growth factor-factor VIII (MFGE8)/lactadherin promotes bladder tumor development. <i>Oncogene</i> , 2011, 30, 642-653.	5.9	49
68	A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. <i>PLoS ONE</i> , 2012, 7, e48993.	2.5	47
69	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
70	C<sc>o</sc>R<sc>eg</sc>N<sc>et</sc>: reconstruction and integrated analysis of co-regulatory networks. <i>Bioinformatics</i> , 2015, 31, 3066-3068.	4.1	46
71	An essential role for decorin in bladder cancer invasiveness. <i>EMBO Molecular Medicine</i> , 2013, 5, 1835-1851.	6.9	45
72	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. <i>Nature Communications</i> , 2021, 12, 5578.	12.8	45

#	ARTICLE	IF	CITATIONS
73	Site-specific .epsilon.-amino monoacylation of pancreatic phospholipase A2. 2. Transformation of soluble phospholipase A2 into a highly penetrating "membrane-bound" form. <i>Biochemistry</i> , 1988, 27, 1688-1694.	2.5	44
74	Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. <i>Genome Biology</i> , 2010, 11, R76.	9.6	44
75	A siRNA screen identifies RAD21 , EIF3H , CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. <i>Carcinogenesis</i> , 2014, 35, 670-682.	2.8	44
76	Recurrent activating mutations of PPAR $\beta$ associated with luminal bladder tumors. <i>Nature Communications</i> , 2019, 10, 253.	12.8	44
77	Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. <i>Oncogene</i> , 2004, 23, 9201-9211.	5.9	43
78	LICORN: learning cooperative regulation networks from gene expression data. <i>Bioinformatics</i> , 2007, 23, 2407-2414.	4.1	40
79	HMCan: a method for detecting chromatin modifications in cancer samples using ChIP-seq data. <i>Bioinformatics</i> , 2013, 29, 2979-2986.	4.1	39
80	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. <i>Genome Medicine</i> , 2020, 12, 85.	8.2	39
81	No evidence of somatic FGFR3 mutation in various types of carcinoma. <i>Oncogene</i> , 2001, 20, 5059-5061.	5.9	38
82	The interaction between the presynaptic phospholipase neurotoxins beta-bungarotoxin and crotoxin and mixed detergent-phosphatidylcholine micelles. A comparison with non-neurotoxic snake venom phospholipases A $_2$ . <i>Journal of Biological Chemistry</i> , 1987, 262, 8966-8974.	3.4	35
83	Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 180-188.	1.6	34
84	APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. <i>European Urology</i> , 2019, 76, 9-13.	1.9	34
85	Epidermal Growth Factor Receptor Regulates Normal Urothelial Regeneration. <i>Laboratory Investigation</i> , 2003, 83, 1333-1341.	3.7	33
86	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 383-386.	1.5	33
87	Pancreatic $\beta$ Cells Cultured from Individual Preneoplastic Foci in a Multistage Tumorigenesis Pathway: a Potentially General Technique for Isolating Physiologically Representative Cell Lines. <i>Molecular and Cellular Biology</i> , 1993, 13, 4223-4232.	2.3	33
88	PPAPDC1B and WHSC1L1 Are Common Drivers of the 8p11-12 Amplicon, Not Only in Breast Tumors But Also in Pancreatic Adenocarcinomas and Lung Tumors. <i>American Journal of Pathology</i> , 2013, 183, 1634-1644.	3.8	32
89	Growth, Differentiation and Senescence of Normal Human Urothelium in an Organ-Like Culture. <i>European Urology</i> , 2004, 45, 799-805.	1.9	29
90	Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2013, 61, 2-25.	5.5	29

#	ARTICLE	IF	CITATIONS
91	A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1. <i>PLoS Genetics</i> , 2016, 12, e1005888.	3.5	29
92	Purification of an acidic phospholipase A2 from <i>Bothrops lanceolatus</i> (fer de lance) venom: Molecular and enzymatic properties. <i>Toxicon</i> , 1994, 32, 1069-1081.	1.6	28
93	The interaction between the presynaptic phospholipase neurotoxins beta-bungarotoxin and crotoxin and mixed detergent-phosphatidylcholine micelles. A comparison with non-neurotoxic snake venom phospholipases A2. <i>Journal of Biological Chemistry</i> , 1987, 262, 8966-74.	3.4	28
94	Neutralization of lethal potency and inhibition of enzymatic activity of a phospholipase A2 neurotoxin, crotoxin, by non-precipitating antibodies (Fab). <i>FEBS Letters</i> , 1989, 244, 167-173.	2.8	27
95	Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. <i>Cancers</i> , 2020, 12, 2714.	3.7	27
96	Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. <i>Oncogene</i> , 1999, 18, 5722-5726.	5.9	26
97	Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status*1. <i>Human Pathology</i> , 2004, 35, 817-824.	2.0	26
98	Quantitative Analysis of Protein Complex Constituents and Their Phosphorylation States on a LTQ-Orbitrap Instrument. <i>Journal of Proteome Research</i> , 2010, 9, 5118-5132.	3.7	26
99	Role of a Kinesin Motor in Cancer Cell Mechanics. <i>Nano Letters</i> , 2019, 19, 7691-7702.	9.1	26
100	Binding of Crotoxin, a Presynaptic Phospholipase A2 Neurotoxin, to Negatively Charged Phospholipid Vesicles. <i>Journal of Neurochemistry</i> , 1989, 53, 1252-1260.	3.9	25
101	Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases. <i>British Journal of Cancer</i> , 2004, 90, 1230-1234.	6.4	25
102	Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine. <i>Journal of Proteome Research</i> , 2017, 16, 1617-1631.	3.7	25
103	p15 INK4b in bladder carcinomas: decreased expression in superficial tumours. <i>British Journal of Cancer</i> , 2001, 85, 1515-1521.	6.4	23
104	Assessing reproducibility of matrix factorization methods in independent transcriptomes. <i>Bioinformatics</i> , 2019, 35, 4307-4313.	4.1	23
105	TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. <i>British Journal of Cancer</i> , 2019, 120, 555-564.	6.4	23
106	Identifying genes from up-down properties of microarray expression series. <i>Bioinformatics</i> , 2005, 21, 3859-3864.	4.1	22
107	Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. <i>International Journal of Cancer</i> , 2012, 130, 1367-1377.	5.1	22
108	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	1.6	22

#	ARTICLE	IF	CITATIONS
109	Crotoxin, a phospholipase A2 neurotoxin from snake venom, interacts with epithelial mammary cells, is internalized and induces secretion. <i>Molecular and Cellular Endocrinology</i> , 1991, 82, 41-50.	3.2	18
110	Selecting biomedical data sources according to user preferences. <i>Bioinformatics</i> , 2004, 20, i86-i93.	4.1	18
111	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. <i>BMC Cancer</i> , 2017, 17, 636.	2.6	18
112	Characterization of a new brain-specific isoform of the EWS oncoprotein. <i>FEBS Journal</i> , 2001, 268, 3483-3489.	0.2	17
113	Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. <i>BMC Cancer</i> , 2007, 7, 58.	2.6	17
114	Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses. <i>Proteomics</i> , 2014, 14, 1333-1342.	2.2	17
115	Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. <i>JAMA Ophthalmology</i> , 2020, 138, 569.	2.5	17
116	Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation. <i>Clinical Cancer Research</i> , 2006, 12, 2937-2943.	7.0	15
117	Gene List significance at-a-glance with GeneValorization. <i>Bioinformatics</i> , 2011, 27, 1187-1189.	4.1	14
118	OUP accepted manuscript. <i>Nucleic Acids Research</i> , 2021, 49, 11005-11021.	14.5	14
119	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100536.	1.1	13
120	Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas. <i>International Journal of Cancer</i> , 2007, 120, 2058-2059.	5.1	12
121	Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation. <i>Experimental Cell Research</i> , 2018, 369, 284-294.	2.6	12
122	Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. <i>Journal of Pathology</i> , 2022, 256, 108-118.	4.5	12
123	Highly Sensitive Detection Method of Retinoblastoma Genetic Predisposition and Biomarkers. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1714-1721.	2.8	12
124	Binding of divalent and trivalent cations with crotoxin and with its phospholipase and its non-catalytic subunits: effects on enzymatic activity and on the interaction of phospholipase component with phospholipids. <i>Lipids and Lipid Metabolism</i> , 1989, 1006, 183-192.	2.6	11
125	Sensitive Allele-Specific PCR Assay Able to Detect FGFR3 Mutations in Tumors and Urine from Patients with Urothelial Cell Carcinoma of the Bladder. <i>Clinical Chemistry</i> , 2005, 51, 1555-1557.	3.2	11
126	New aminopyrimidine derivatives as inhibitors of the TAM family. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 789-801.	5.5	11



#	ARTICLE	IF	CITATIONS
127	A prospective multicenter study on bladder cancer: the COBLAnCE cohort. <i>BMC Cancer</i> , 2016, 16, 837.	2.6	11
128	Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5510-5530.	3.0	11
129	PRC2-independent chromatin compaction and transcriptional repression in cancer. <i>Oncogene</i> , 2015, 34, 741-751.	5.9	10
130	PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2019, 18, 3471-3480.	1.8	10
131	Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives. <i>Cancers</i> , 2021, 13, 87.	3.7	10
132	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. <i>Cancers</i> , 2021, 13, 673.	3.7	9
133	Functions of fibroblast and transforming growth factors in primary organoid-like cultures of normal human urothelium. <i>Laboratory Investigation</i> , 1996, 75, 147-56.	3.7	8
134	Pepper: cytoscape app for protein complex expansion using protein-protein interaction networks. <i>Bioinformatics</i> , 2014, 30, 3419-3420.	4.1	7
135	SegCorr a statistical procedure for the detection of genomic regions of correlated expression. <i>BMC Bioinformatics</i> , 2017, 18, 333.	2.6	5
136	Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. <i>Molecular Carcinogenesis</i> , 2005, 42, 142-149.	2.7	4
137	Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. <i>Molecular Carcinogenesis</i> , 2010, 49, 25-31.	2.7	4
138	Network Transformation of Gene Expression for Feature Extraction. , 2012, , .		3
139	Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. <i>Eur Urol</i> 2019, 76:9-13. <i>European Urology</i> , 2020, 77, e26-e27.	1.9	3
140	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. <i>Journal of Pathology</i> , 2022, , .	4.5	3
141	Identification of deregulation mechanisms specific to cancer subtypes. <i>Journal of Bioinformatics and Computational Biology</i> , 2021, 19, 2140003.	0.8	2
142	Triple extraction method enables high quality mass spectrometry-based proteomics and phosphoproteomics for eventual multi-omics integration studies. <i>Proteomics</i> , 2021, 21, 2000303.	2.2	2
143	Crotoxin, a phospholipase A2 neurotoxin from snake venom, interacts with epithelial mammary cells, is internalized and induces secretion. <i>Molecular and Cellular Endocrinology</i> , 1992, 84, 155.	3.2	1
144	Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. <i>Molecular and Cellular Oncology</i> , 2015, 2, e999507.	0.7	1

#	ARTICLE	IF	CITATIONS
145	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-438. European Urology, 2020, 77, 436-438.	1.9	1
146	Identification of Deregulated Transcription Factors Involved in Specific Bladder Cancer Subtypes. , 0, , .		1
147	Local Pattern Discovery in Array-CGH Data. Lecture Notes in Computer Science, 2005, , 135-152.	1.3	1
148	Le récepteur de type 3 des FGF (FGFR3) : de la chondrodysplasie au cancer de la vessie. Medecine/Sciences, 2001, 17, 1189-1191.	0.2	0